FVD
DividendFirst Trust Value Line Dividend Index Fund
First Trust · Tracks Value Line Dividend Index · Inception Aug 19, 2003
Composite score
Based on a 0.62% expense ratio.
Based on $8.04B in net assets.
Top-10 holdings represent 4.5% of net assets.
Dividend base · ETF wrapper · 2.29% TTM yield.
The composite is a weighted average of the four core sub-scores above (cost, tax efficiency, liquidity, concentration). Missing sub-scores fall back to the per-category median when the category has at least 50% data coverage, so funds without (e.g.) parsed N-PORT holdings aren't accidentally boosted by renormalization. Tracking quality is shown where computable but isn't currently part of the composite weighting. See methodology for formulas, the tracking-quality partial-coverage rationale, and the dimensions we deliberately don't score (methodology v0.5.1).
Use FVD in our tools
Tool · Cost
Compare FVD's fee against another fund
Compounds the 0.62% expense ratio against a peer over decades.
Tool · Overlap
Compare FVD's holdings with peers
Pairwise holdings heatmap, pre-loaded with similar Dividend funds.
Tool · TLH
Find a tax-loss harvesting partner for FVD
Ranks every catalog fund by holdings overlap, flags wash-sale risk.
Tool · Placement
Where should this fund live across your accounts?
Asset-location optimizer — places each fund in taxable / tax-deferred / Roth.
Top holdings
| # | Holding | Weight |
|---|---|---|
| 1 | Entergy Corporation | 0.46% |
| 2 | Rio Tinto PLC | 0.46% |
| 3 | Sanofi SA | 0.45% |
| 4 | America Movil S.A.B. de C.V. | 0.45% |
| 5 | AstraZeneca PLC | 0.45% |
| 6 | Landstar System Inc. | 0.45% |
| 7 | Bristol-Myers Squibb Company | 0.45% |
| 8 | GSK plc | 0.44% |
| 9 | AbbVie Inc. | 0.44% |
| 10 | The Campbells Co. | 0.44% |
Compare FVD with another fund
Or skim the closest-overlap funds below.
Similar ETFs by holdings overlap
Open FVD at a brokerage
Affiliate links — opening an account through these earns PlainIndex a one-time referral. Scoring is computed before any affiliate consideration; see our methodology and funding disclosure.